Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

RDO nets $106.7mm for Idenix

Executive Summary

Antivirals developer Idenix Pharmaceuticals Inc. netted $106.7mm through the sale of 16.4mm common shares at $6.50 (an 11% discount) to entities managed by The Baupost Group, which now increases its stake in Idenix to 35% as a result of the financing.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies